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Abstract 
The heat-stable enterotoxins are a family of low molecular weight, cysteine rich peptide toxins which are one of the major causes of 
watery diarrhea in children and adults. These toxins bind to a cell surface receptor in intestinal cells and mediate their action through 
elevation of intracellular cyclic GMP. We have generated a monoclonal antibody to these peptide toxins which is able to neutralise the 
activity of the peptides in a human colonic cell line, the T84 cell line. The monoclonal antibody, ST:G8, appears to be directed to an 
epitope distinct from antibodies previously generated, and prior incubation of this antibody, or Fab generated from this antibody, with full 
length STh and STp peptides prevents cGMP accumulation i T84 cells. This inhibition is a direct result of the antibody preventing 
binding of the peptides to the receptor. ST:G8 Mab does not recognize a 13-mer biologically active analog of STp, comprising the core 
sequence of STp peptide, suggesting that it is directed to a region in the N-terminus of the peptides, which may modulate receptor 
interaction/activation. The antibody recognizes a conformational epitope in the ST peptides, since reduction and carboxyamidation f ST 
abolishes antibody cross-reactivity. Differential cross-reactivity of the Mab with STh and STp peptides, which differ markedly only in 
their N-termini, suggests that this antibody recognizes a distinct conformation in the two peptides, which is essential for receptor 
interaction. 
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I. Introduction 
The heat-stable nterotoxins (ST) are a family of low 
molecular weight peptides produced by a variety of 
pathogenic bacteria, and are one of the major causes of 
watery diarrhea the world over [1,2]. These toxins are 
characterised by the presence of three disulphide bridges 
which are essential for full biological activity [3], and ST 
peptides produced by different pathogenic bacteria differ 
in the amino acids between the cysteine residues and in 
sequences towards the N-terminus of the central cysteine 
rich core [4-6] (Table 1). In fact, a 13-mer sequence 
Abbreviations: BSA, bovine serum albumin; CCEL, 13-mer peptide 
corresponding to core sequence of STp; Dq"F, dithiothreitol; ELISA, 
enzyme linked immunosorbent assay; Mab, monoclonal antibody; PBS, 
phosphate buffered saline; ST, heat-stable enterotoxin; STh, ST peptide 
of the human variety; STp, ST peptide of the porcine variety; STY72F, 
ST peptide with C-terminal tyrosine replaced by phenylalanine 
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containing the 6 cysteine residues in the toxin has biologi- 
cal activity in the suckling mouse assay [7,8], which is the 
model system usually used for in vivo assays for the ST 
peptides. 
The ST peptides bind to a receptor present in intestinal 
cells. Cloning and biochemical characterisation of the re- 
ceptor from both rat and human tissue indicates that it is a 
member of the family of membrane bound guanylyl cy- 
clases [9]. Membrane-bound guanylyl cyclases serve as 
receptors for a number of different peptide ligands [10], 
and ligand binding to the extracellular domain of these 
receptors activates the cytoplasmic guanylyl cyclase do- 
main, resulting in elevated levels of cGMP within the 
cells. In the case of ST peptides, the events involved 
subsequent to cGMP production are poorly defined, but 
probably occur by the cross-activation of protein kinase A 
by cGMP, and increased chloride secretion through the 
cystic fibrosis transmembrane r gulator [11]. 
We have been interested in studying the interaction of 
ST peptides with the human receptor present in a human 
colonic cell line, the T84 cell line [12]. This cell line 
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Table 1 
Amino acid sequences of peptides used in this study 
Peptide Sequence Species 
STh NSSNYCCELO~NPACTC-CY E. coli 
STp NTFY~'~CELCCNPACAGCY E. coli 
STY72F NSSNYCCEI//~SqPACTGCF E. coli 
CCEL CCELCCNPACAGC E. coli 
Yersinia ST S DWDC2CDVCCN PACAC~ Yersinia 
enterocolitica 
mimics the normal human intestine in showing vectorially 
directed ion transport, and harbours the receptor for the ST 
peptides [13]. We have shown that a variety of ST peptides 
produced by a number of pathogenic bacteria, are able to 
elicit elevated levels of cGMP within T84 cells, presum- 
ably by interacting with the receptor present in these cells 
[14]. We have characterised this receptor in T84 cells, and 
partial purification indicated that it too is a member of the 
membrane associated form of guanylyl cyclase [15]. 
Monoclonal antibodies (MAb) serve as useful tools to 
delineate regions of a ligand which play an important role 
in interacting with the receptor. A number of monoclonal 
antibodies have been raised to ST peptides, some of them 
sequence- and some of them conformational-specific [16- 
18]. In a few cases, these antibodies are neutralising, either 
in the suckling mouse assay or in inhibiting cGMP produc- 
tion in T84 cells [17,18]. Interestingly, most of these 
antibodies have been mapped to the C-terminus core of the 
ST peptides, which is sufficient for full biological activity. 
In one case, a single residue at the N-terminus of STh, 
outside the core sequence, was essential for recognition of 
the antibody [18]. 
We have earlier suggested that apart from the C-terminus 
core of the ST peptides, sequences extended at the N- 
terminus may also modulate ST activity [14]. We have 
based this hypothesis on the fact that peptides which differ 
only marginally in the C-terminus core sequence have 
markedly different activities in a biological assay [14]. In 
this report, we show that a neutralising Mab which could 
be directed to the N-terminus of ST peptides is able to 
inhibit ST interaction with the receptor in T84 cells. 
2. Materials and methods 
2.1. Purification of ST peptides 
STh and STY72F peptides were purified from hyperex- 
pressing strains as detailed earlier [15,19]. Purity of the 
peptides was checked by reverse phase high performance 
liquid chromatography and peptides quantitated by amino 
acid analysis as described [20]. Yersinia ST and the 13-mer 
peptide corresponding tothe core sequence of STp (CCEL) 
were synthesised and air oxidised to obtain biologically 
active peptides as described earlier [14]. STp was procured 
from Sigma (Mo., USA), and peptide quantitated after 
reconstitution. Bioactivity was monitored by elevation of 
intracellular cGMP levels on application of the peptides to 
monolayer cultures of T84 cells. 
2.2. Culture and maintenance of T84 cells 
T84 cells were procured from ATCC (CCL-248) and 
cultured as described earlier [14]. Following application of 
ST to monolayer cultures of T84 cells, intracellular levels 
of cGMP were monitored 15-30 min later by lysis of the 
cells in 0.1 M citric acid [14]. Radioimmunoassay was 
performed using 125I-labelled succinyl tyrosyl methyl ester 
of cGMP. Under these conditions, less than 10% of cGMP 
produced was secreted into the culture supernatant [14]. 
2.3. Generation and purification of Mab ST:G8 
Purified STY72F peptide was conjugated to bovine 
serum albumin using glutaraldehyde and BALB/c mice 
were immunised with 50 /zg of the conjugate in complete 
Freund's adjuvant, intradermally. Fourteen days following 
primary injection, mice were boosted with the same amount 
of conjugate in incomplete adjuvant. One week following 
the booster, the mice were bled through the tail vein and 
serum titres of antibodies to ST peptides were monitored 
by ELISA. Mice which had significant levels of circulating 
antibodies were boosted with daily i.p. injections of conju- 
gate (10 /zg in PBS) for four days prior to fusion. Fusion 
was carried out by established protocols [12], and culture 
supernatants were tested by ELISA against ST coated 
plates (see below). The clone ST:G8 was established fol- 
lowing two rounds of subcloning, and cells used for the 
generation of ascites fluid. IgG from the ascites fluid was 
purified by Protein A agarose (Pierce Chemical Company, 
Rockford, USA) and tested for subclass and light chain 
specificity by using subclass and isotype specific antisera 
(Sigma, St. Louis, MO, USA). 
Fab fragments of the IgG was prepared by digestion of 
the purified IgG by papain. Briefly, 500 /zg of purified 
IgG was incubated in 100 mM sodium acetate buffer, pH 
5.5 containing 10 mM 2-mercaptoethanol, 1 mM EDTA 
and 5 /zg of papain dissolved in acetate buffer. Digestion 
was continued for 6 h at 37°C in vacuo and quenched by 
the addition of 150 mM iodoacetamide. The mixture was 
dialysed against PBS, checked for digestion by SDS gel 
electrophoresis [21] and the mixture was added to 100 /zl 
of Protein A agarose. Mixing was continued for 2 h at 
25°C to remove Fc and any undigested IgG. The unbound 
fraction was then checked by SDS gel electrophoresis, and 
protein quantitated by the Bradford method [22]. 
2.4. ELISA procedure for ST peptides 
The ST peptides were dissolved at concentrations of 2 
/zg/ml in 10 mM sodium phosphate buffer, pH 7.2, 
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containing 0.9% (w/v)  sodium chloride (PBS) and 100/xl 
aliquots were added to ELISA plates (high binding, 
NUNC). Peptide was allowed to adsorb to the plates at 4°C 
for 16 h. Plates were washed, blocked with PBS containing 
0.2% (w/v)  bovine serum albumin (BSA), and antibody 
added suitably diluted in PBS/BSA/0.1% (v/v)  Tween 
20 (usually 1:1000 ascites fluid) and allowed to interact 
with the peptide for 1 h at 25°C. The bound antibody was 
monitored using a horseradish peroxidase-anti-mouse IgG 
conjugate (Bangalore Genei, India), and colour developed 
using 3,3',5,5'-tetramethylbenzidine as a substrate. 
were prepared from T84 cells as described earlier [15]. 
Radiolabelled STY72F, (10-10 M) was incubated with the 
ascitic fluid (1:100 dilution), in 50 mM Hepes, pH 7.2, 4 
mM MgC12, 1 /zg/ml aprotinin, 1 /~g/ml leupeptin and 
0.2% BSA in a total volume of 100/zl for 1 h at 37°C, and 
then added to 50 /zg of T84 membrane protein, either in 
the presence or absence of unlabelled STh (10 -7  M)  under 
conditions described in detail earlier [15]. Following incu- 
bation for 1 h at 37°C, the samples were filtered through 
glass fibre filters (GF/B, Whatman) and counted. 
2.5. Reduction and carboxyamidation fST peptides 3. Results 
Peptides (10 5 M) were incubated in 100 mM Tris-HC1 
buffer, pH 8.8, containing 1mM DTT, at 37°C, for 2 h. At 
the end of this time, iodoacetamide (5 mM) was added and 
incubation continued for a further 30 min in the dark at 
25°C. The peptides were then used directly in a radioim- 
munoassay to monitor inhibition of 125I-labelled STY72F 
(approx. 50 000 cpm) binding to the suitably diluted anti- 
body. Controls included incubations performed in the pres- 
ence of equivalent concentrations of native ST peptides. 
2.6. Radioimmunoassay using radiolabelled STY72F and 
Mab 
STY72F peptide was iodinated as described earlier and 
purified by reverse phase HPLC [15]. Suitable dilutions of 
ST:G8 were incubated with approx. 20 000-50 000 cpm of 
radiolabelled peptide in PBS containing 0.2% (w/v)  BSA 
for 1 h at 37°C, in a total volume of 300 /xl. Included 
during the assay were varying concentrations of unlabelled 
STh, STp and STY72F peptide. Incubation was continued 
for 1 h following which 1 ml of a chilled 0.2% (w/v)  
charcoal suspension (Norit A, Gibco) in PBS/BSA was 
added, and incubation continued for 5 min at 25°C. The 
samples were then centrifuged, supernatant discarded and 
charcoal bound radioactivity, which represented ST pep- 
tide unbound to antibody, was monitored. 
2.7. Neutralisation of ST activi~ in T84 cells 
3.1. Production and characterisation of the Mab ST:G8 
The Mab was raised to the STY72F peptide, which we 
have characterised arlier as a potent ligand for the human 
ST receptor present in T84 cells [15]. The particular clone 
that was identified was initially selected by its ability to 
interact with STh and STY72F peptides coated to the 
ELISA plate. The Mab ST:G8 was of the IgG2a subclass 
with K light chain. Fig. 1 shows the reaction of the peptide 
to various purified and synthetic peptides corresponding to
different ST peptides produced by E. coli and Yersinia 
enterocolitica. ST:G8 was able to recognize full length 
peptides produced by E. coli but did not react with the 
synthetic ore sequence corresponding to a 13-mer peptide 
from the STp peptide. This suggested that the Mab was 
directed to an epitope not present in the 13-met biologi- 
cally active peptide, but required residues towards the 
N-terminus of the full length ST peptide. The Mab was 
specific to the peptides produced by E. coli and did not 
interact with the Yersinia ST (Fig. 1). 
3.2. Neutralising effect of the Mab 
In order to test the ability of ST:G8 to inhibit the 
bioactivity of ST peptides, we have monitored the produc- 
tion of cGMP in T84 human colonic cells, on application 
of ST peptides previously incubated with the antibody. 
ST peptides, (10 -8 M), were incubated with 15 p,g of 
purified IgG or varying concentrations of Fab fragment 
prepared from the purified IgG fraction, for 1 h at 37°C. in 
DMEM:F12 (Gibco) containing 0.2% BSA. At the end of 
this time, the solution was applied to T84 cells, which had 
been washed with DMEM:F12 medium. The cells were 
incubated for 30 min at 37°C, in an atmosphere of 5% 
CO 2, following which cells were washed and lysed in 400 
/zl 0.1 M citric acid. Samples of the cell lysate were 
assayed for cGMP production by radioimmunoassay s 
detailed earlier. 
To monitor the inhibition of radiolabelled STY72F 
binding to the receptor present in T84 cells, membranes 
i' 
O. 
STh STY72F YersiniaST CCEL 
Fig. 1. Interaction of ST:G8 Mab with ST peptides. ST peptides were 
immobilised on ELISA plates and ST:G8 ascites fluid at a dilution of 
1:50000 was added to the plates. Following incubation for t h, bound 
antibody was detected using an anti-mouse IgG-horse radish peroxidase 
conjugate. Values represent the mean (+ S.D.) of duplicate or triplicate 
determinations, with each experiment repeated thrice. 
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Fig. 2. Neutralisation of ST activity in T84 cells by ST:G8. Peptides 
(10 -s  M) were incubated with purified IgG ST:G8 Mab as detailed in 
Section 2, and then applied to T84 cells in culture, cGMP produced was 
monitored by radioimmunoassay. Values represent the mean (+ S.D.) of 
duplicate incubations, with each experiment repeated thrice. 
Fig. 2 shows that in agreement with the data from the 
ELISA results, the antibody was able to neutralise the 
activity of E. coli STh and STp peptides, but not the 
activity of the 13-mer core sequence of STp or Yersinia 
ST. In order to determine whether this neutralisation was 
due to inhibition of peptide binding to the receptor, or in 
preventing a conformational change induced on ligand 
binding to the receptor present in T84 cells, we checked 
the ability of ST:G8 to inhibit the binding of labelled 
STY72F to the receptor in T84 cells. We incubated excess 
Mab ST:G8 with radiolabelled STY72F and then added it 
to membranes prepared from T84 cells, either in the 
presence or absence of unlabelled STh peptide. As can be 
seen from Fig. 3, the antibody was able to prevent he 
binding of radiolabelled ST peptide to its receptor, as 
efficiently as a large excess of unlabelled STh peptide. 
This clearly indicates that binding of the antibody to 
STY72F prevents its further interaction with the receptor, 
therefore inhibiting cGMP accumulation i the T84 cells, 
as shown in Fig. 2. 
It is likely that there could be a steric constraint in 
allowing ST interaction with the receptor following anti- 
body binding, perhaps contributed by the Fc fragment of 
the whole antibody molecule. We therefore prepared the 
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Fig. 4. Neutralisation of STh activity by Fab fragment prepared from 
purified ST:G8 Mab. Fab fragment was prepared from purified ST:G8 
IgG, and incubated at indicated concentrations with STh (10 -8 M) prior 
to addition to T84 cells, cGMP produced was monitored by radioim- 
munoassay. Values represent the mean (+ S.D.) of duplicate determina- 
tions, with the experiment repeated thrice. 
Fab fragment from purified whole Mab and the data in Fig. 
4 show that the Fab fragment is also able to inhibit cGMP 
production on addition of ST to the T84 monolayer. While 
this still does not rule out the possibility of steric hin- 
drance preventing ST bound to antibody from interacting 
with the receptor, it does suggest hat the residues which 
may modulate receptor interaction are blocked following 
incubation with the antibody. It is pertinent to note that 
some antibodies to STh have been shown to be poorly 
neutralisable or even non-neutralising [14,18], suggesting 
that antibody interaction alone with the peptide may not 
prevent interaction of the peptide with the receptor. 
In order to determine whether the antibody is directed 
to a sequential epitope or a conformational epitope, we 
reduced and carboxyamidated ST peptides and determined 
their reactivity with the antibody in a liquid phase radioim- 
munoassay. STh and STY72F peptides were reduced with 
DTT and carboxyamidated with iodoacetamide. The data 
shown in Fig. 5 indicates that reduced peptide were unable 
to inhibit the binding of labelled STY72F to the antibody, 
confirming that the antibody recognizes a conformation 
,,~ 
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+blab  
-STh +STh 
Fig. 3. Monoclonal antibody ST:G8 inhibits binding of STY72F to the ST 
receptor in T84 cells. ST:G8 Mab was incubated with r25I-labelled 
STY72F, and the mixture added to T84 membranes, either in the presence 
or absence of a large excess of STh peptide. Receptor bound radioactivity 
was monitored following filtration through glass fibre filters. Values 
represent the mean (+ S.D.) of duplicate determinations, with the experi- 
ment repeated thrice. 
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Fig. 5. Monoclonal antibody ST:G8 is directed to a conformational 
epitope in ST peptides. STh and STY72F peptides were reduced and 
carboxyamidated and used in radioimmunoassay to monitor inhibition of 
binding of native I25I-labelled STY72F to ST:G8 Mab. Untreated peptide 
was also incubated in a similar manner and radioactivity associated with 
the antibody monitored following charcoal treatment. Values represent 
the mean (_+S.D.) of duplicate determinations with each experiment 
repeated at least thrice. 
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Fig. 6. Inhibition of binding of labelled STY72F to ST:G8 by ST 
peptides. Indicated concentrations of STh, STp or STY72F were incu- 
bated along with radiolabelled STY72F and purified ST:G8 IgG (0.5 
/zg/ml final dilution). Binding to antibody was monitored following 
charcoal addition. Values represent the mean_S.D, of duplicate or 
triplicate determinations with experiments performed atleast hrice. 
presumably in the N-terminus of the ST peptide, which is 
destroyed on reduction and carboxyamidation. 
The data presented here suggest hat the Mab ST:G8 
reacts with a conformational epitope present outside the 
core sequence of the ST peptides, and could be directed to 
an epitope composed of the N-terminal sequences along 
with the core sequence. We have shown here that the Mab 
recognizes STh, STY72F and STp sequences, the latter 
differing in sequence at its N-terminus (Table 1). We 
monitored the inhibition of binding of labelled STY72F to 
the antibody brought about by varying concentrations of
STh, STp and STY72F. The data shown in Fig. 6 indicate 
that the concentration of STp required to inhibit labelled 
STY72F binding to the receptor is nearly 10-fold higher 
than STh, strongly suggesting that antibody recognition 
prefers a conformation contributed by the N-terminus of 
STh, rather then STp. It is interesting to note that all the 3 
peptides used in this assay have a residue following the 
13-mer core sequence (Y or F; Table 1) indicating that the 
C-terminal residue following the core sequence, may not 
contribute significantly to the epitope involved in receptor 
recognition. 
4. Discussion 
In this report, we describe the development of a Mab to 
the family of ST peptides produced by E. coli. We have 
shown that the antibody is able to inhibit the binding of the 
peptide to the human receptor and therefore neutralise 
cGMP production on ST application in T84 cells. We have 
demonstrated that this antibody is conformational specific 
and tried to address the problem of steric hindrance of 
antibody-ligand-receptor binding by showing that the Fab 
fragment prepared from the monoclonal antibody, is able 
to inhibit binding as well. 
A number of groups have raised monoclonal antibodies 
to the ST peptides, and some have suggested their applica- 
tion for diagnostic purposes [17,23]. In all cases, as indeed 
in ours, the antibodies raised to the E. coli peptides do not 
interact with the peptides produced by Yersinia or non-01 
Vibrio [17,18]. This clearly indicates that there are unique 
sequences in the latter peptides that modulate their interac- 
tion with the receptor, and which differ markedly in the E. 
coli and Yersinia peptides. It is therefore interesting to 
note that a small peptide such as ST may harbour more 
than one conformational epitope in its stretch. 
The amino acid sequences which are essential for inter- 
action with various monoclonal antibodies to STh have 
been determined by Takeda et al. [18]. A tyrosine at the 
C-terminus of STh was critical for one Mab interaction, 
and an epitope to another distinct Mab was suggested to be 
present owards the N-terminus of ST peptides. We feel 
that ST:G8 defines an epitope different o studies detailed 
earlier in that there does not appear to be a selectivity for 
the presence of a tyrosine at the C-terminal residue, since 
ST:G8 is able to interact with STY72F peptide with com- 
parable affinity to STh. We also have evidence that the 
antibody is able to recognize a mutant STh peptide where 
the 5th amino acid from the N-terminus, tyrosine, has been 
replaced by tryptophan (data not shown). We therefore feel 
that this antibody recognizes a conformation at the N- 
terminus, generated by the correctly folded core sequence, 
which could be important in ligand-receptor interactions. 
The crystal structure has been determined for an analog 
of the core sequence of the ST peptides, and defines three 
distinct conformations in the peptide [24]. However, no 
information is available to date as to a possible structure 
adopted by the N-terminal sequences of the peptides, 
which, as we have shown in this study, directly affects 
ligand binding to the receptor. It is conceivable that bind- 
ing of an antibody to the N-terminus of the ST peptide 
could distort the final conformation of the C-terminus of 
the ST peptide and therefore prevent receptor interaction. 
Such information can only be obtained from the crystal 
structure of this antibody along with ST peptides. 
It has been suggested that the 13-met core sequence of 
the ST peptides is sufficient for full biological activity. 
However, no precise measurements have been made of the 
affinity of the 13-mer peptide to the receptor, nor a 
comparison with the native full length STp. It has been 
difficult to obtain a potent antiserum to this region, proba- 
bly due to the similarity in structure of this region with a 
naturally occurring peptide, guanylin, which has been 
shown to interact with the same receptor as ST in T84 
cells [25]. We would like to determine the epitope to which 
ST:G8 is directed by identifying the conformation adopted 
by ST in its interaction with ST:G8. This epitope could be 
identified by the use of constrained phage display libraries 
[26], and the sequence thus identified used for the genera- 
tion of neutralising antibodies. It would be interesting to 
determine if such a sequence could inhibit or modulate ST 
interaction with the receptor. Such studies are underway in 
the laboratory. 
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